Papers/PMID:40719561
A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.
Hepatology communications2025The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
L-ascorbic acid — increases acute kidney injury incidence (any grade)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“A higher incidence of acute kidney injury (AKI) was found in the vitamin C-treated group (68.4%) than in the control group (35.0%), which was statistically significant (p=0.04), according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition.”
Quoted verbatim from A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.. - Study
- RCT
- Dose
- 1500 mg intravenous bolus in 100 mL saline during the anhepatic phase, once
- Population
- Adults undergoing liver transplantation, single-centre pilot trial of 39 patients; a single 1500 mg intravenous ascorbic acid bolus before graft reperfusion versus 0.9% saline
A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.2025PMID:40719561Permalink